Treatment of Genital Fungal Infections

Diagnosis

• Examination of discharge characteristics, measurement of pH, and microscopic examination with saline and 10% potassium hydroxide (KOH) preparations are recommended for the diagnosis of vaginitis, as suggested by the CDC and the American Academy of Pediatrics (AAP) 1
• Microscopic examination with saline and 10% KOH preparations can demonstrate yeast or hyphae, and culture can be used for definitive identification in recurrent or severe cases, as recommended by the Infectious Diseases Society of America 2
• Clinical presentation, patient history, laboratory tests, and biopsy in chronic or suspicious lesions are used to diagnose balanitis and balanopostitis, with a strength of evidence level of high, as recommended by the National Institute for Health and Care Excellence guidelines and the European Association of Urology 3, 4, 5
• The symptoms of balanitis can be described as follows:

6, 7

First-Line Treatments

• The Infectious Diseases Society of America recommends topical antifungal agents, such as clotrimazole or miconazole, applied for 7-14 days as a first-line treatment for uncomplicated vulvovaginal candidiasis 7, 8
• A single 150-mg oral dose of fluconazole is also recommended as a first-line treatment for uncomplicated vulvovaginal candidiasis 7
• For children weighing 45 kg or more who can tolerate oral medication, the Infectious Diseases Society of America recommends fluconazole 150 mg single dose 7
• The Infectious Diseases Society of America recommends combination therapy with oral fluconazole 150 mg as a single dose plus topical clotrimazole cream applied to affected areas twice daily for 7-14 days for fungal infections 2, 7

Second-Line Treatments

• Boric acid suppositories are recommended as a second-line treatment for non-albicans Candida infections, particularly C. glabrata, that are unresponsive to standard azole therapies 7
• Boric acid can be used as an alternative when conventional treatments fail 8
• Nystatin intravaginal suppositories (100,000 units daily for 14 days) are an option for C. glabrata infections 7
• Topical 17% flucytosine cream alone or combined with 3% amphotericin B cream daily for 14 days can be used to treat C. glabrata infections 7
• Alternative oral agents, such as itraconazole 200 mg daily for 7 days, may be considered for non-responsive cases or for patients who cannot tolerate or have contraindications to fluconazole, as recommended by the Infectious Diseases Society of America 9

Maintenance Therapy

• After successful treatment, maintenance therapy with fluconazole 150 mg weekly for 6 months can be considered for recurrent infections 7
• For recurrent balanitis of suspected fungal origin, the Infectious Diseases Society of America recommends fluconazole 150 mg weekly for 6 months after initial control of the acute episode 2, 7

Prevention and Risk Factors

• Good hygiene, including gentle cleaning with warm water and complete drying after bathing, can help prevent balanitis and balanopostitis, with a strength of evidence level of high, as recommended by the CDC guidelines 3
• Control of underlying conditions such as diabetes is important in managing balanitis and balanopostitis, with a strength of evidence level of high, as recommended by the CDC guidelines 3
• Uncircumcised status, poor hygiene, phimosis, diabetes mellitus, immunosuppression, and chronic inflammation are risk factors for developing balanitis, with a strength of evidence level of high, as noted by the American Academy of Dermatology 3
• Tobacco use is also a risk factor for balanitis, with a strength of evidence level of moderate, as stated by the National Comprehensive Cancer Network guidelines 3

Follow-Up and Complications

• Reassessment of patients with vaginitis or balanitis within 1-2 weeks is recommended to ensure resolution of symptoms, and considering alternative diagnosis if no improvement after 72 hours of appropriate therapy, as recommended by the AAP and CDC 1, 10
• Lifelong follow-up is recommended for patients with lichen sclerosus due to the risk of malignancy, with a strength of evidence level of high, as recommended by the British Association of Dermatologists 4, 3
• Balanitis and balanopostitis can lead to complications such as phimosis, urethral stricture, sexual dysfunction, and malignant transformation, especially in cases of lichen sclerosus (risk of 2-9%), with a strength of evidence level of moderate, as stated by the American Urological Association guidelines 3
• Patients with lichen sclerosus are at risk of developing penile carcinoma, which carries a 2-9% risk, with a strength of evidence level of high, as recommended by the British Association of Dermatologists 4, 3